

Corifact (coagulation Factor XIII concentrate [human])
Effective 01/01/2024

| | | | |
|------------------------------|-------------------------------------------------------------------------------------------------------------|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Plan | <input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange | Program Type | <input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy |
| Benefit | <input checked="" type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit | | |
| Specialty Limitations | This medication has been designated specialty and must be filled at a contracted specialty pharmacy. | | |
| Contact Information | Medical and Specialty Medications | | |
| | All Plans | Phone: 877-519-1908 | Fax: 855-540-3693 |
| Exceptions | Non-Specialty Medications | | |
| | All Plans | Phone: 800-711-4555 | Fax: 844-403-1029 |
| Exceptions | N/A | | |

Overview

Corifact is indicated in adult and pediatric patients with congenital Factor XIII deficiency for routine prophylactic treatment and peri-operative management of surgical bleeding.

All other indications are considered experimental/investigational and not medically necessary.

Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted when the following criteria is met:

1. Member has a diagnosis of Factor XIII deficiency.

Continuation of Therapy

Reauthorization may be granted for continued treatment when the member is experiencing benefit from therapy (e.g., reduced frequency or severity of bleeds).

Limitations

1. Initial approvals and reauthorizations will be granted for 12 months.

References

1. Corifact [package insert]. Kankakee, IL: CSL Behring LLC; September 2020.
2. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Revised April 2022. MASAC Document #272. https://www.hemophilia.org/sites/default/files/document/files/272_Treatment.pdf. Accessed September 26, 2022.

3. [Mumford AD](#), [Ackroyd S](#), [Alikhan R](#), et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. [Br J Haematol](#). 2014;167(3):304-26.
4. AHFS DI (Adult and Pediatric) [database online]. Bethesda, MD. American Society of Health System Pharmacists, Inc. Electronic version. Updated March 28, 2022. Available with subscription. URL: <http://online.lexi.com/lco>. Accessed September 26, 2022.

Review History

12/13/2023: Reviewed at Dec P&T, switched from SGM to Custom. Effective 1/1/2024

